OFIX

SEC source: 0001209191-21-025417 · doc4.xml · derivative · entry 6

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,394

Underlying: Common Stock · 13,394 shares

Expires not disclosed

F2 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as April 1, 2021 to April 1, 2024. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P 600 Health Care Equipment & Services Industry Group Index (S6HCES) as of April 1, 2021, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

F2 · derivative.expiration_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as April 1, 2021 to April 1, 2024. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P 600 Health Care Equipment & Services Industry Group Index (S6HCES) as of April 1, 2021, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

SEC source: 0001209191-21-025417 · doc4.xml · nonDerivative · entry 4

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,841

SEC source: 0001209191-21-025417 · doc4.xml · nonDerivative · entry 3

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,708

SEC source: 0001209191-21-025417 · doc4.xml · nonDerivative · entry 2

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,737

SEC source: 0001209191-21-025417 · doc4.xml · nonDerivative · entry 1

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,122

F1 · shares: Represents time-based vesting restricted stock units that vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 1, 2021.

SEC source: 0001209191-21-025412 · doc4.xml · derivative · entry 6

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Develop. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,229

Underlying: Common Stock · 12,229 shares

Expires not disclosed

F2 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as April 1, 2021 to April 1, 2024. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P 600 Health Care Equipment & Services Industry Group Index (S6HCES) as of April 1, 2021, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

F2 · derivative.expiration_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as April 1, 2021 to April 1, 2024. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P 600 Health Care Equipment & Services Industry Group Index (S6HCES) as of April 1, 2021, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

SEC source: 0001209191-21-025412 · doc4.xml · nonDerivative · entry 4

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Develop. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,552

SEC source: 0001209191-21-025412 · doc4.xml · nonDerivative · entry 3

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Develop. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,381

SEC source: 0001209191-21-025412 · doc4.xml · nonDerivative · entry 2

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Develop. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,366

SEC source: 0001209191-21-025412 · doc4.xml · nonDerivative · entry 1

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Develop. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,720

F1 · shares: Represents time-based vesting restricted stock units that vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 1, 2021.

SEC source: 0001209191-21-025408 · doc4.xml · derivative · entry 3

Kenny Kevin J. · CIK 0001520400 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,229

Underlying: Common Stock · 12,229 shares

Expires not disclosed

F2 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as April 1, 2021 to April 1, 2024. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P 600 Health Care Equipment & Services Industry Group Index (S6HCES) as of April 1, 2021, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

F2 · derivative.expiration_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as April 1, 2021 to April 1, 2024. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P 600 Health Care Equipment & Services Industry Group Index (S6HCES) as of April 1, 2021, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

SEC source: 0001209191-21-025408 · doc4.xml · nonDerivative · entry 2

Kenny Kevin J. · CIK 0001520400 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,268

SEC source: 0001209191-21-025408 · doc4.xml · nonDerivative · entry 1

Kenny Kevin J. · CIK 0001520400 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,021

F1 · shares: Represents time-based vesting restricted stock units that vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 1, 2021.

SEC source: 0001209191-21-025402 · doc4.xml · derivative · entry 3

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,764

Underlying: Common Stock · 40,764 shares

Expires not disclosed

F2 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as April 1, 2021 to April 1, 2024. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P 600 Health Care Equipment & Services Industry Group Index (S6HCES) as of April 1, 2021, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

F2 · derivative.expiration_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as April 1, 2021 to April 1, 2024. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P 600 Health Care Equipment & Services Industry Group Index (S6HCES) as of April 1, 2021, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

SEC source: 0001209191-21-025402 · doc4.xml · nonDerivative · entry 2

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 113,722

SEC source: 0001209191-21-025402 · doc4.xml · nonDerivative · entry 1

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,506

F1 · shares: Represents time-based vesting restricted stock units that vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 1, 2021.

SEC source: 0001209191-20-061955 · doc4.xml · nonDerivative · entry 1

Kenny Kevin J. · CIK 0001520400 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,792

SEC source: 0001209191-20-056465 · doc4.xml · nonDerivative · entry 1

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,181

SEC source: 0001209191-20-052236 · doc4.xml · nonDerivative · entry 1

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Develop. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,965

SEC source: 0001209191-20-050324 · doc4.xml · derivative · entry 2

Gonsalves Paul · CIK 0001824319 · President, Global Extremities

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,945

Underlying: Common Stock · 32,945 shares

Expires 2030-09-11

F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, September 11, 2020.

SEC source: 0001209191-20-050324 · doc4.xml · nonDerivative · entry 1

Gonsalves Paul · CIK 0001824319 · President, Global Extremities

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,624

F1 · shares: Represents time-based vesting restricted stock units that vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, September 11, 2020.

SEC source: 0001209191-20-050550 · doc4.xml · nonDerivative · entry 1

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Develop. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,515

SEC source: 0001209191-20-046214 · doc4.xml · nonDerivative · entry 1

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,647

SEC source: 0001209191-20-041974 · doc4.xml · nonDerivative · entry 1

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,706

SEC source: 0001209191-20-041397 · doc4.xml · nonDerivative · entry 2

Finegan Michael · CIK 0001391402 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,175

SEC source: 0001209191-20-041308 · doc4.xml · nonDerivative · entry 1

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,880

SEC source: 0001209191-20-041303 · doc4.xml · nonDerivative · entry 2

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,162

SEC source: 0001209191-20-041397 · doc4.xml · nonDerivative · entry 1

Finegan Michael · CIK 0001391402 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,538

SEC source: 0001209191-20-041303 · doc4.xml · nonDerivative · entry 1

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,535

SEC source: 0001209191-20-035666 · doc4.xml · nonDerivative · entry 1

MATRICARIA RONALD A · CIK 0001221872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 164,122

F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The award vests in full on the first anniversary of the grant date, June 8, 2020.

SEC source: 0001209191-20-035668 · doc4.xml · derivative · entry 2

Hannon Jason · CIK 0001330401 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24.701

Underlying: Common Stock · 24,701 shares

Expires 2030-06-08

F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, June 8, 2020.

SEC source: 0001209191-20-035668 · doc4.xml · nonDerivative · entry 1

Hannon Jason · CIK 0001330401 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,588

F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The award vests in full on the first anniversary of the grant date, June 8, 2020.

SEC source: 0001209191-20-035663 · doc4.xml · nonDerivative · entry 1

Hinrichs James F. · CIK 0001506974 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,514

F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The award vests in full on the first anniversary of the grant date, June 8, 2020.

SEC source: 0001209191-20-035661 · doc4.xml · nonDerivative · entry 1

Lukianov Alexis V · CIK 0001289410 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,083

F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The award vests in full on the first anniversary of the grant date, June 8, 2020.

SEC source: 0001209191-20-035659 · doc4.xml · nonDerivative · entry 1

MARKS LILLY · CIK 0001645735 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,794

F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The award vests in full on the first anniversary of the grant date, June 8, 2020.

SEC source: 0001209191-20-035657 · doc4.xml · nonDerivative · entry 1

Paolucci Michael E · CIK 0001599463 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,779

F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The award vests in full on the first anniversary of the grant date, June 8, 2020.

SEC source: 0001209191-20-035655 · doc4.xml · nonDerivative · entry 1

Sainz Maria · CIK 0001437768 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,871

F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The award vests in full on the first anniversary of the grant date, June 8, 2020.

SEC source: 0001209191-20-035652 · doc4.xml · nonDerivative · entry 1

SICARD JOHN · CIK 0001734027 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,919

F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The award vests in full on the first anniversary of the grant date, June 8, 2020.

SEC source: 0001209191-20-035647 · doc4.xml · derivative · entry 1

Kenny Kevin J. · CIK 0001520400 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,485

Underlying: Common Stock · 10,485 shares

Expires not disclosed

F1 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as June 8, 2020 to June 8, 2023. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of June 8, 2020, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

F1 · derivative.expiration_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as June 8, 2020 to June 8, 2023. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of June 8, 2020, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

SEC source: 0001209191-20-035645 · doc4.xml · derivative · entry 1

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,534

Underlying: Common Stock · 11,534 shares

Expires not disclosed

F1 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as June 8, 2020 to June 8, 2023. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of June 8, 2020, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

F1 · derivative.expiration_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as June 8, 2020 to June 8, 2023. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of June 8, 2020, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

SEC source: 0001209191-20-035640 · doc4.xml · derivative · entry 1

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,058

Underlying: Common Stock · 12,058 shares

Expires not disclosed

F1 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as June 8, 2020 to June 8, 2023. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of June 8, 2020, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

F1 · derivative.expiration_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as June 8, 2020 to June 8, 2023. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of June 8, 2020, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

SEC source: 0001209191-20-035636 · doc4.xml · derivative · entry 1

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,872

Underlying: Common Stock · 45,872 shares

Expires not disclosed

F1 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as June 8, 2020 to June 8, 2023. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of June 8, 2020, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

F1 · derivative.expiration_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as June 8, 2020 to June 8, 2023. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of June 8, 2020, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

SEC source: 0001209191-20-035294 · doc4.xml · derivative · entry 3

Finegan Michael · CIK 0001391402 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,750 shares

Expires 2023-09-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, September 26, 2013.

SEC source: 0001209191-20-035294 · doc4.xml · nonDerivative · entry 2

Finegan Michael · CIK 0001391402 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,933

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.22 to $37.76, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.

SEC source: 0001209191-20-035294 · doc4.xml · nonDerivative · entry 1

Finegan Michael · CIK 0001391402 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,683

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-023335 · doc4.xml · nonDerivative · entry 2

Finegan Michael · CIK 0001391402 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,933

SEC source: 0001209191-20-023323 · doc4.xml · nonDerivative · entry 3

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,009

SEC source: 0001209191-20-023315 · doc4.xml · nonDerivative · entry 3

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,636

SEC source: 0001209191-20-023335 · doc4.xml · nonDerivative · entry 1

Finegan Michael · CIK 0001391402 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,252

SEC source: 0001209191-20-023332 · doc4.xml · derivative · entry 2

Kenny Kevin J. · CIK 0001520400 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,542

Underlying: Common Stock · 24,542 shares

Expires 2030-04-01

F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 1, 2020.